- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04086043
The MILESTONE Study
September 10, 2019 updated by: Gao-jun Teng, Zhongda Hospital
MultI-eLectrode EndovaScular denervaTiOn in patieNts With Type 2 Diabetes mEllitus (MILESTONE) Study
Sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (T2DM), so it is assumed that denervation might reduce sympathetic overactivity and improve glucose metabolism and insulin sensitivity.
The purpose of this study is to evaluate the effects of multi-electrode catheter-based endovascular denervation on glucose metabolism and insulin sensitivity in patients with T2DM.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Sympathetic overactivity induces insulin resistance and type 2 diabetes mellitus (T2DM), so it is assumed that denervation might improve glucose metabolism and insulin sensitivity.
Some clinical studies have shown that glucose metabolism is improved in patients with resistant hypertension both 1 and 3 months after denervation, and fasting glucose, insulin and C-peptide decreased significantly as did insulin resistance assessed by HOMA-IR.
But in some clinical studies, denervation did not lead to a significant improvement of insulin sensitivity ≤12 months after treatment, and no effect in systemic sympathetic activity was observed after denervation.
Therefore, the efficacy of denervation on glucose metabolism is still in controversy.
The investigators wish to investigate the effect of multi-electrode catheter-based endovascular denervation on glucose metabolism and insulin sensitivity in patients with T2DM.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tao Pan, PhD
- Phone Number: +86-15850651223
- Email: 15850651223@126.com
Study Contact Backup
- Name: Gao-Jun Teng,, MD
- Phone Number: +86 25 83272121
- Email: gjteng@seu.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Recruiting
- Zhongda Hospital, Southeast University
-
Contact:
- Gao-Jun Teng, MD
- Phone Number: +86 25 83272121
- Email: gjteng@seu.edu.cn
-
Principal Investigator:
- Gao-Jun Teng, MD
-
Contact:
- Tao Pan, PhD
- Phone Number: +86-15850651223
- Email: 15850651223@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Over 18 years and ≤ 70 years old
- Able and willing to provide informed consent
- Patients with established type II diabetes mellitus (HbA1C>7.5%, diet or oral hypoglycaemic agents)
- Clinical stable as demonstrated by no change in background anti-diabetic medication in the last 30 days.
- Anticipated that patients are able to maintain a stable dose of medication for the duration of the study
Exclusion Criteria:
- Arterial anatomy ineligible for endovascular denervation
- History of prior renal artery intervention including balloon angioplasty, stenting or previous renal denervation
- Type 1 diabetes mellitus
- Pregnant, nursing or planning to be pregnant
- Orthostatic hypotension
- eGFR <30 ml/min (MDRD formula)
- Patients that have allergy to contrast agent
- Myocardial infarction, unstable angina pectoris, coronary bypass or percutaneous angioplasty within 3 months before inclusion
- Cerebrovascular accidents and alimentary tract hemorrhage within 3 months before inclusion
- Any medical condition which, in the investigators opinion, may adversely affect the participants safety in the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endovascular Denervation
|
multi-electrode catheter-based endovascular denervation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Oral Glucose Tolerance Test from baseline to 6 months
Time Frame: 6 months
|
To investigate the influence of endovascular denervation on Oral Glucose Tolerance Test (OGTT).
|
6 months
|
Changes in glycosylated hemoglobin from baseline to 6 months
Time Frame: 6 months
|
To investigate the influence of endovascular denervation on glycosylated hemoglobin (HbA1c).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Oral Glucose Tolerance Test up to 2 years
Time Frame: 3, 12 and 24 months
|
To investigate the influence of endovascular denervation on Oral Glucose Tolerance Test (OGTT).
|
3, 12 and 24 months
|
Changes in glycosylated hemoglobin up to 2 years
Time Frame: 3, 12 and 24 months
|
To investigate the influence of endovascular denervation on glycosylated hemoglobin (HbA1c).
|
3, 12 and 24 months
|
Changes in insulin up to 2 years
Time Frame: 3, 6, 12 and 24 months
|
To investigate the influence of endovascular denervation on insulin.
|
3, 6, 12 and 24 months
|
Changes in catecholamine up to 2 years
Time Frame: 3, 6, 12 and 24 months
|
To investigate the influence of endovascular denervation on catecholamine.
|
3, 6, 12 and 24 months
|
Changes in glucagon up to 2 years
Time Frame: 3, 6, 12 and 24 months
|
To investigate the influence of endovascular denervation on glucagon.
|
3, 6, 12 and 24 months
|
Changes in blood pressure up to 2 years
Time Frame: 3, 6, 12 and 24 months
|
To investigate the influence of endovascular denervation on blood pressure.
|
3, 6, 12 and 24 months
|
Changes in creatinine up to 2 years
Time Frame: 3, 6, 12 and 24 months
|
To investigate the influence of endovascular denervation on creatinine.
|
3, 6, 12 and 24 months
|
Changes in blood urea nitrogen (BUN) up to 2 years
Time Frame: 3, 6, 12 and 24 months
|
To investigate the influence of endovascular denervation on BUN.
|
3, 6, 12 and 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 10, 2019
Primary Completion (Anticipated)
September 9, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
September 5, 2019
First Submitted That Met QC Criteria
September 10, 2019
First Posted (Actual)
September 11, 2019
Study Record Updates
Last Update Posted (Actual)
September 11, 2019
Last Update Submitted That Met QC Criteria
September 10, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDNT2DM-2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on Endovascular Denervation
-
Zhongda HospitalRecruiting
-
Shanghai Golden Leaf MedTec Co. LtdUnknownStomach Cancer | Bile Duct Cancer | Pancreas Cancer | Liver Cancer
-
Zhongda HospitalRecruiting
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
-
Hippocration General HospitalReCor Medical, Inc.RecruitingStress | Anxiety | Hypertension ArterialGreece
-
Vivek ReddyCompletedVentricular TachycardiaUnited States, Czechia, Russian Federation
-
Vivek ReddyCompletedAtrial Fibrillation | Uncontrolled HypertensionUnited States, Czechia, Russian Federation
-
Ramathibodi HospitalPranungkraw General HospitalCompletedOsteoarthritis, KneeThailand